In the presence of genetic alterations of BCL2 and BCL6, which inactivate the normal apoptotic pathways of the cell, MYC overexpression results in a much more uncontrolled proliferative drive: this explains why DH lymphomas present greater biological aggressiveness and poor response to conventional treatments [50]. This evidence concerns the gene BCL6 and lymphoma.